Association of MORC2 expression with progression-free survival in cervical cancer patients treated with concurrent chemoradiotherapy.

Autor:	He J; Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China.; Department of Oncology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University), Ganzhou, Jiangxi Province, China., Liao XH; Department of Oncology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University), Ganzhou, Jiangxi Province, China., Zhong BD; Department of Oncology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University), Ganzhou, Jiangxi Province, China., Liu AW; Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2024 Sep 20; Vol. 103 (38), pp. e39299.
DOI:	10.1097/MD.0000000000039299
Abstrakt:	MORC family CW-type zinc finger 2 (MORC2) is a newly identified chromatin remodeling protein, and has been proposed as a prognostic biomarker associated with survival in some types of human cancer, but the role of MORC2 in cervical cancer remains unknown. Here, we investigated the role of MORC2 expression in predicting the survival outcomes of locally advanced cervical cancer patients treated with cisplatin-based concurrent chemoradiotherapy (CCRT). In this retrospectively study, we detected MORC2 immunohistochemical expression on 55 biopsies from patients who underwent CCRT. The association between the MORC2 expression and various clinicopathological characteristics were analyzed, as were association between MORC2 expression and locoregional failure and progression-free survival (PFS) of cervical cancer patients. MORC2 expression was positively associated with pelvic node metastasis and locoregional failure. Higher MORC2 expression was a significant indicator of worse PFS. Our results suggest that MORC2 expression may be a prognostic indicator in patients with locally advanced cervical cancer undergoing CCRT. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu